Memantin Ratiopharm Gmbh (Memantine Hydrochloride)

Memantine blocks the NMDA‑type glutamate receptor in a non‑competitive manner. By limiting excessive calcium entry caused by overstimulation, it reduces excitotoxic neuronal damage while allowing normal synaptic activity, supporting neuronal health in Alzheimer’s disease.

The specific dose and titration schedule are determined by the prescribing clinician based on the patient’s condition, renal function, and tolerability. Healthcare professionals adjust the regimen to achieve the best therapeutic outcome.

Safety data for memantine in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas many other Alzheimer’s agents are acetylcholinesterase inhibitors. Memantine is typically used for moderate disease stages and may be combined with an inhibitor for broader symptom control, offering a different mechanism of action.

Store the product at ambient temperature, below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight, and extreme heat to maintain stability and potency.

The medication is taken orally, usually as a tablet, with or without food. Patients should follow the dosing instructions provided by their prescriber and swallow the tablet whole with water.

Serious risks include seizures, severe allergic reactions such as rash or swelling, hallucinations or psychosis, and cardiac arrhythmias. Patients should seek immediate medical attention if any of these symptoms occur.

Memantin is contraindicated in patients with known hypersensitivity to memantine or any excipients in the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA antagonists.